Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2009 1
2010 1
2011 1
2014 4
2015 6
2016 6
2017 4
2018 9
2019 5
2020 8
2021 13
2022 11
2023 8
2024 11
2025 19
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; PASADENA ClinicalTrial …
CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with …
Genome-wide association study of long COVID.
Lammi V, Nakanishi T, Jones SE, Andrews SJ, Karjalainen J, Cortés B, O'Brien HE, Ochoa-Guzman A, Fulton-Howard BE, Broberg M, Haapaniemi HH, Kanai M, Pirinen M, Schmidt A, Mitchell RE, Mousas A, Mangino M, Huerta-Chagoya A, Sinnott-Armstrong N, Cirulli ET, Vaudel M, Kwong ASF, Maiti AK, Marttila MM, Posner DC, Rodriguez AA, Batini C, Minnai F, Dearman AR, Warmerdam CAR, Sequeros CB, Winkler TW, Jordan DM, Rešcenko R, Miano L, Lane JM, Chung RK, Guillen-Guio B, Leavy OC, Carvajal-Silva L, Aguilar-Valdés K, Frangione E, Guare L, Vergasova E, Marouli E, Striano P, Zainulabid UA, Kumar A, Ahmad HF, Edahiro R, Azekawa S; Long COVID Host Genetics Initiative; FinnGen; VA Million Veteran Program; MexGen-COVID Initiative; DBDS Genomic Consortium; GEN-COVID Multicenter Study; PHOSP-COVID Collaborative Group; GENCOV Study; Estonian Biobank Research Team; Luoh SW, Erikstrup C, Pedersen OBV, Lerner-Ellis J, Colombo A, Grzymski JJ, Ishii M, Okada Y, Beckmann ND, Kumari M, Wagner R, Heid IM, John C, Short PJ, Magnus P, Ansone L, Valenti LVC, Lee SA, Wain LV, Verdugo RA, Banasik K, Geller F, Franke LH, Rakitko A, Duncan EL, Renieri A, Tsilidis KK, de Cid R, Niavarani A, Abner E, Tusié-Luna T, Ver… See abstract for full author list ➔ Lammi V, et al. Nat Genet. 2025 Jun;57(6):1402-1417. doi: 10.1038/s41588-025-02100-w. Epub 2025 May 21. Nat Genet. 2025. PMID: 40399555 Free PMC article.
Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD.
Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, Anton J, Hofer M, Chkirate B, Bouayed K, Tugal-Tutkun I, Kuemmerle-Deschner J, Agostini H, Federici S, Arnoux A, Piedvache C, Ozen S; PEDBD group. Koné-Paut I, et al. Ann Rheum Dis. 2016 Jun;75(6):958-64. doi: 10.1136/annrheumdis-2015-208491. Epub 2015 Dec 23. Ann Rheum Dis. 2016. PMID: 26698843 Free article.
FINDINGS: In total, 42 centres from 12 countries included 230 patients; data for 219 (M/F ratio=1) could be analysed. The experts classified 156 patients (71.2%) as having confirmed BD. ...
FINDINGS: In total, 42 centres from 12 countries included 230 patients; data for 219 (M/F ratio=1) could be analysed. The experts cla …
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Seppi K, Monnet A, Shariati N, Ricci B, Rutten-Jacobs L, Respondek G, Kustermann T, Taylor KI, Trundell D, Fontoura P, Doody R, Svoboda H, Bonni A; PADOVA Investigators and Prasinezumab Study Group. Nikolcheva T, et al. Parkinsonism Relat Disord. 2025 Mar;132:107257. doi: 10.1016/j.parkreldis.2024.107257. Epub 2024 Dec 29. Parkinsonism Relat Disord. 2025. PMID: 39798255 Free article.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
[(18)F]FDG-PET/CT Radiomics and Artificial Intelligence in Lung Cancer: Technical Aspects and Potential Clinical Applications.
Manafi-Farid R, Askari E, Shiri I, Pirich C, Asadi M, Khateri M, Zaidi H, Beheshti M. Manafi-Farid R, et al. Semin Nucl Med. 2022 Nov;52(6):759-780. doi: 10.1053/j.semnuclmed.2022.04.004. Epub 2022 Jun 15. Semin Nucl Med. 2022. PMID: 35717201 Free article. Review.
Lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide. Molecular imaging using [(18)F]fluorodeoxyglucose Positron Emission Tomography and/or Computed Tomography ([(18)F]FDG-PET/CT) plays an essential role in the diagnos …
Lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide. Molecular imaging using [(18)F] …
Diagnostic Performance of [(18)F]F-FDG Positron Emission Tomography (PET) in Non-Ophthalmic Malignant Melanoma: A Systematic Review and Meta-Analysis of More Than 10,000 Melanoma Patients.
Zamani-Siahkali N, Mirshahvalad SA, Pirich C, Beheshti M. Zamani-Siahkali N, et al. Cancers (Basel). 2024 Jan 2;16(1):215. doi: 10.3390/cancers16010215. Cancers (Basel). 2024. PMID: 38201642 Free PMC article. Review.
We described the diagnostic performance of [(18)F]F-FDG-PET in malignant melanoma by conducting a comprehensive systematic review and meta-analysis of the existing literature. ...Thus, [(18)F]F-FDG-PET is a valuable diagnostic modality for melanoma ass …
We described the diagnostic performance of [(18)F]F-FDG-PET in malignant melanoma by conducting a comprehensive systematic rev …
Prognostic value of 2-[(18)F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy.
Schweighofer-Zwink G, Manafi-Farid R, Kölblinger P, Hehenwarter L, Harsini S, Pirich C, Beheshti M. Schweighofer-Zwink G, et al. Eur J Radiol. 2022 Jan;146:110107. doi: 10.1016/j.ejrad.2021.110107. Epub 2021 Dec 13. Eur J Radiol. 2022. PMID: 34922117 Free article.
PURPOSE: The 2-fluorodeoxyglucose positron emission tomography/computed tomography (2-[(18)F]FDG PET/CT) is used for the evaluation of response to immunotherapy in malignant melanoma. ...The 3-month follow-up 2-[(18)F]FDG PET/CT is of particular importance in this r …
PURPOSE: The 2-fluorodeoxyglucose positron emission tomography/computed tomography (2-[(18)F]FDG PET/CT) is used for the evaluation o …
2-[(18)F]FDG PET/CT radiomics in lung cancer: An overview of the technical aspect and its emerging role in management of the disease.
Manafi-Farid R, Karamzade-Ziarati N, Vali R, Mottaghy FM, Beheshti M. Manafi-Farid R, et al. Methods. 2021 Apr;188:84-97. doi: 10.1016/j.ymeth.2020.05.023. Epub 2020 Jun 1. Methods. 2021. PMID: 32497604 Review.
Lung cancer is the most common cancer, worldwide, and a major health issue with a remarkable mortality rate. 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (2-[(18)F]FDG PET/CT) plays an indispensable role in the management of lun …
Lung cancer is the most common cancer, worldwide, and a major health issue with a remarkable mortality rate. 2-[(18)F]fluoro-2-deoxy- …
96 results